水田 秀一 みずた しゅういち 先生

来歴等

略歴

1986年 愛知県済生会病院 研修
1988年 県西部浜松医療センター血液科
1990年 都立駒込病院輸血科
1993年 名古屋大学医学部付属病院第一内科 医員
1998年 愛知県厚生連更生病院 輸血部長
2002年 愛知県厚生連更生病院 血液内科統括部長
2003年 藤田保健衛生大学血液化学療法科 助教授（現・准教授）
2016年 国立病院機構豊橋医療センター血液内科 部長・輸血部長
2017年 国立病院機構豊橋医療センター 内科系診療部長
2018年 金沢医科大学血液免疫内科 臨床教授
2024年 金沢医科大学総合内科 講座教授

論文

• Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Different impact of BCR-ABL transcripts on allogeneic hematopoietic cell transplantation from different graft sources for Ph + ALL with minimal residual disease. Am J Hematol. 2019 Nov;94(11):E301-E305.

  Nishiwaki S, Mizuta S, Ohashi K, Fukuda T, Uchida N, Tachibana T, Onizuka M, Ozawa Y, Onishi Y, Takahashi S, Eto T, Nakamae H, Tanaka J, Ichinohe T, Atsuta Y, Kako S

• Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer Sci. 2019 Oct;110(10):3255-3266.

  Akahoshi Y, Nishiwaki S, Mizuta S, Ohashi K, Uchida N, Tanaka M, Fukuda T, Ozawa Y, Takahashi S, Onizuka M, Shiratori S, Nakamae H, Kanda Y, Ichinohe T, Atsuta Y, Kako S

• Adult Lymphoma Working Group of the JSHCT. Allogeneic haematopoietic stem cell transplantation for primary mediastinal large B-cell lymphoma patients relapsing after high dose chemotherapy with autologous stem cell transplantation: data from the Japan Society for Haematopoietic Cell Transplantation registry. Br J Haematol. 2019 Sep;186(6):e219-e223.

  Kondo E, Shimizu-Koresawa R, Chihara D, Mizuta S, Izutsu K, Ikegame K, Uchida N, Fukuda T, Ichinohe T, Atsuta Y, Suzuki R

• Allogeneic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Biol Blood Marrow Transplant. 2019 Aug;25(8):1597-1602.

  Hangai M, Urayama KY, Tanaka J, Kato K, Nishiwaki S, Koh K, Noguchi M, Kato K, Yoshida N, Sato M, Goto H, Yuza Y, Hashii Y, Atsuta Y, Mizuta S, Kato M

• Risk factors and timing of autologous stem cell transplantation for patients with peripheral T-cell lymphoma. Int J Hematol. 2019 Feb;109(2):175-186.

  Yamasaki S, Chihara D, Kim SW, Kawata T, Mizuta S, Ago H, Chou T, Yamane T, Uchiyama H, Oyake T, Miura K, Saito B, Taji H, Nakamae H, Miyamoto T, Fukuda T, Kanda J, Atsuta Y, Suzuki R

• Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Additional Cytogenetic Abnormalities with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia on Allogeneic Stem Cell Transplantation in the Tyrosine Kinase Inhibitor Era. Biol Blood Marrow Transplant. 2018 Oct;24(10):2009-2016.

  Akahoshi Y, Mizuta S, Shimizu H, Uchida N, Fukuda T, Kanamori H, Onizuka M, Ozawa Y, Ohashi K, Ohta S, Eto T, Tanaka J, Atsuta Y, Kako S

• Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study. Int J Clin Oncol. 2018 Oct;23(5):980-988.

  Mizuta S, Sawa M, Tsurumi H, Matsumoto K, Miyao K, Hara T, Takahashi T, Sakemura R, Kojima H, Kohno A, Oba MS, Morita S, Sakamoto J, Emi N

• Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL. Ann Hematol. 2018 Sep;97(9):1535-1545.

  Hatta Y, Mizuta S, Matsuo K, Ohtake S, Iwanaga M, Sugiura I, Doki N, Kanamori H, Ueda Y, Yoshida C, Dobashi N, Maeda T, Yujiri T, Monma F, Ito Y, Hayakawa F, Takeuchi J, Kiyoi H, Miyazaki Y, Naoe T

• DADI Trial Group, Japan. Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment. Clin Lymphoma Myeloma Leuk. 2018 May;18(5):353-360.

  Okada M, Imagawa J, Tanaka H, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Mizuta S, Hashino S, Nomura T, Shikami M, Fukutani H, Ohe Y, Kosugi H, Shibayama H, Maeda Y, Fukushima T, Yamazaki H, Tsubaki K, Kukita T, Adachi Y, Nataduka T, Sakoda H, Yokoyama H, Okamoto T, Shirasugi Y, Onishi Y, Nohgawa M, Yoshihara S, Morita S, Sakamoto J, Kimura S

• Improved prognosis with additional medium-dose VP16 to CY/TBI in allogeneic transplantation for high risk ALL in adults. Am J Hematol. 2018 Jan;93(1):47-57.

  Arai Y, Kondo T, Shigematsu A, Tanaka J, Ohashi K, Fukuda T, Hidaka M, Kobayashi N, Iwato K, Sakura T, Onizuka M, Ozawa Y, Eto T, Kurokawa M, Kahata K, Uchida N, Atsuta Y, Mizuta S, Kako S

• Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older. Biol Blood Marrow Transplant. 2017 Dec;23(12):2079-2087.

  Kawamura K, Kako S, Mizuta S, Ishiyama K, Aoki J, Yano S, Fukuda T, Uchida N, Ozawa Y, Eto T, Iwato K, Kanamori H, Kahata K, Kondo T, Sawa M, Ichinohe T, Atsuta Y, Kanda Y

• GvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemia. Bone Marrow Transplant. 2017 Sep;52(9):1261-1267.

  Terakura S, Kuwatsuka Y, Yamasaki S, Wake A, Kanda J, Inamoto Y, Mizuta S, Yamaguchi T, Uchida N, Kouzai Y, Aotsuka N, Ogawa H, Kanamori H, Nishiwaki K, Miyakoshi S, Onizuka M, Amano I, Fukuda T, Ichinohe T, Atsuta Y, Murata M, Teshima T

• Japan Society for Haematopoietic Cell Transplantation. Increased non-relapse mortality due to high-dose cytarabine plus CY/TBI in BMT/PBSCT for acute lymphoblastic leukaemia in adults. Br J Haematol. 2017 Jul;178(1):106-111.

  Arai Y, Kondo T, Shigematsu A, Tanaka J, Ohashi K, Fukuda T, Kawakita T, Mori T, Hoshino T, Onizuka M, Ozawa Y, Yoshida S, Ueda Y, Mizuno I, Atsuta Y, Mizuta S

• Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Am J Hematol. 2017 Apr;92(4):367-374.

  Fujisawa S, Mizuta S, Akiyama H, Ueda Y, Aoyama Y, Hatta Y, Kakihana K, Dobashi N, Sugiura I, Onishi Y, Maeda T, Imai K, Ohtake S, Miyazaki Y, Ohnishi K, Matsuo K, Naoe T

• Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Comparison of Cyclophosphamide Combined with Total Body Irradiation, Oral Busulfan, or Intravenous Busulfan for Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2016 Dec;22(12):2194-2200.

  Mitsuhashi K, Kako S, Shigematsu A, Atsuta Y, Doki N, Fukuda T, Kanamori H, Onizuka M, Takahashi S, Ozawa Y, Kurokawa M, Inoue Y, Nagamura-Inoue T, Morishima Y, Mizuta S, Tanaka J

• High-dose cytarabine added to CY/TBI improves the prognosis of cord blood transplantation for acute lymphoblastic leukemia in adults: a retrospective cohort study. Bone Marrow Transplant. 2016 Dec;51(12):1636-1639.

  Arai Y, Kondo T, Shigematsu A, Tanaka J, Takahashi S, Kobayashi T, Uchida N, Onishi Y, Ishikawa J, Kanamori H, Sawa M, Yokota A, Kouzai Y, Takanashi M, Ichinohe T, Atsuta Y, Mizuta S

• TP53 mutations in older adults with acute myeloid leukemia. Int J Hematol. 2016 Apr;103(4):429-435.

  Yanada M, Yamamoto Y, Iba S, Okamoto A, Inaguma Y, Tokuda M, Morishima S, Kanie T, Mizuta S, Akatsuka Y, Okamoto M, Emi N

• Transcriptional activation of platelet-derived growth factor receptor α and GS homeobox 2 resulting from E26 transformation-specific variant 6 translocation in a case of acute myeloid leukemia with t(4;12)(q12;p13). Int J Lab Hematol. 2016 Apr;38(2):e15-18.

  Abe A, Mizuta S, Okamoto A, Yamamoto Y, Kameyama T, Mayeda A, Emi N

• Nagoya Blood and Marrow Transplantation Group. Influence of melphalan plus fludarabine-conditioning regimen in elderly patients aged ⩾55 years with hematological malignancies. Bone Marrow Transplant. 2016 Jan;51(1):157-160.

  Miyao K, Sawa M, Kuwatsuka Y, Ozawa Y, Kato T, Kohno A, Sao H, Nishida T, Iida H, Naito K, Tsurumi H, Taji H, Mizuta S, Kusumoto S, Nakase K, Morishita Y, Kawashima N, Miyamura K, Murata M

• Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: a study from the adult ALL WG of the JSHCT. Bone Marrow Transplant. 2016 Jan;51(1):43-50.

  Nishiwaki S, Imai K, Mizuta S, Kanamori H, Ohashi K, Fukuda T, Onishi Y, Takahashi S, Uchida N, Eto T, Nakamae H, Yujiri T, Mori S, Nagamura-Inoue T, Suzuki R, Atsuta Y, Tanaka J

• Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma. Cancer Sci. 2015 Nov;106(11):1576-1581.

  Okamoto A, Yanada M, Miura H, Inaguma Y, Tokuda M, Morishima S, Kanie T, Yamamoto Y, Mizuta S, Akatsuka Y, Yoshikawa T, Mizoguchi Y, Nakamura S, Okamoto M, Emi N

• Adult Acute Lymphoblastic Leukemia Working Group of Japan Society for Hematopoietic Cell Transplantation (JSHCT). Analysis of outcomes following autologous stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia during first complete remission. Haematologica. 2014 Nov;99(11):e228-230.

  Kato H, Kawase T, Kako S, Mizuta S, Kurokawa M, Mori T, Ohashi K, Iwato K, Miyamura K, Hidaka M, Sakamaki H, Suzuki R, Morishima Y, Tanaka J

• Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL-positive acute lymphoblastic leukemia. Blood. 2014 Apr 10;123(15):2325-2332.

  Mizuta S, Matsuo K, Nishiwaki S, Imai K, Kanamori H, Ohashi K, Fukuda T, Onishi Y, Miyamura K, Takahashi S, Onizuka M, Atsuta Y, Suzuki R, Morishima Y, Kato K, Sakamaki H, Tanaka J

• High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transplant. 2014 May;20(5):684-689.

  Chihara D, Izutsu K, Kondo E, Sakai R, Mizuta S, Yokoyama K, Kaneko H, Kato K, Hasegawa Y, Chou T, Sugahara H, Henzan H, Sakamaki H, Suzuki R, Suzumiya J

• Reduced-intensity allogeneic stem cell transplantation for patients aged 50 years or older with B-cell ALL in remission: a retrospective study by the Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2013 Nov;48(12):1513-1518.

  Kanamori H, Mizuta S, Kako S, Kato H, Nishiwaki S, Imai K, Shigematsu A, Nakamae H, Tanaka M, Ikegame K, Yujiri T, Fukuda T, Minagawa K, Eto T, Nagamura-Inoue T, Morishima Y, Suzuki R, Sakamaki H, Tanaka J

• Prognostic factors influencing clinical outcome of allogeneic hematopoietic stem cell transplantation following imatinib-based therapy in BCR-ABL-positive ALL. Blood Cancer J. 2012 May;2(5):e72.

  Mizuta S, Matsuo K, Maeda T, Yujiri T, Hatta Y, Kimura Y, Ueda Y, Kanamori H, Usui N, Akiyama H, Takada S, Yokota A, Takatsuka Y, Tamaki S, Imai K, Moriuchi Y, Miyazaki Y, Ohtake S, Ohnishi K, Naoe T

• Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia. 2011 Jan;25(1):41-47.

  Mizuta S, Matsuo K, Yagasaki F, Yujiri T, Hatta Y, Kimura Y, Ueda Y, Kanamori H, Usui N, Akiyama H, Miyazaki Y, Ohtake S, Atsuta Y, Sakamaki H, Kawa K, Morishima Y, Ohnishi K, Naoe T, Ohno R

• Long-term follow-up of 14 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia following autologous bone marrow transplantation in first complete remission. Int J Hematol. 2007 Feb;85(2):140-145.

  Mizuta S, Kohno A, Morishita Y, Atsuta Y, Sao H, Miyamura K, Sakamaki H, Ueda R, Morishima Y

• Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia. 2002 Jul;16(7):1259-1266.

  Takeuchi J, Kyo T, Naito K, Sao H, Takahashi M, Miyawaki S, Kuriyama K, Ohtake S, Yagasaki F, Murakami H, Asou N, Ino T, Okamoto T, Usui N, Nishimura M, Shinagawa K, Fukushima T, Taguchi H, Morii T, Mizuta S, Akiyama H, Nakamura Y, Ohshima T, Ohno R

• Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation. Nagoya BMT Group. Bone Marrow Transplant. 1999 Oct;24(7):777-784.

  Mizuta S, Ito Y, Kohno A, Kiyoi H, Miyamura K, Tanimoto M, Takamatsu J, Naoe T, Morishima Y, Ueda R, Saito H